Overview of Dr. Niravath
Dr. Polly Niravath is an oncologist in Houston, TX and is affiliated with multiple hospitals in the area, including Houston Methodist Hospital, Houston Methodist Sugar Land Hospital, Houston Methodist Willowbrook Hospital, Houston Methodist Baytown Hospital, Houston Methodist West Hospital, Houston Methodist The Woodlands Hospital, Houston Methodist Clear Lake Hospital, and CHI St Luke's Health - Baylor St Luke's Medical Center. She received her medical degree from University of California, Irvine, School of Medicine and has been in practice 21 years. Dr. Niravath accepts several types of health insurance, listed below. She is one of 104 doctors at Houston Methodist Hospital and one of 100 doctors at CHI St Luke's Health - Baylor St Luke's Medical Center who specialize in Oncology. She has more than 40 publications and over 500 citings.
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011- Baylor College of MedicineResidency, Internal Medicine, 2005 - 2008
University of California, Irvine, School of MedicineClass of 2005
Certifications & Licensure
TX State Medical License 2007 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Start of enrollment: 2007 Dec 01
- HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
- Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast Cancer Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- A phase II study of docetaxel and pembrolizumab plus Interleukin-12 gene therapy in non-metastatic, anthracycline-refractory triple negative breast cancer (INTEGRAL).Polly Niravath, Ivonne Uzair, Kai Sun, Hanh Mai, Jian Guan
Clinical Cancer Research. 2026-02-09 - 4 citationsCharacterization of the Breast Cancer Liver Metastasis Microenvironment via Machine Learning Analysis of the Primary Tumor Microenvironment.Dylan A Goodin, Eric Chau, Junjun Zheng, Cailin O'Connell, Anjana Tiwari
Cancer Research Communications. 2024-10-01 - 22 citationsA Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.Kai Sun, Yitian Xu, Licheng Zhang, Polly Niravath, Jorge Darcourt
Clinical Cancer Research. 2022-10-14
Press Mentions
The Eating and Drinking Habits That Affect Your Risk of Breast CancerOctober 11th, 2022- The Eating and Drinking Habits That Affect Your Breast Cancer RiskOctober 11th, 2022
- Study Shows the Pain of Carrying Debt Can Be Physical, TooOctober 4th, 2021
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
